Brief: Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI

Alkermes

03/01/2024 12:43

Jan 3 (Reuters) - Alkermes Plc  ALKS.O :
    * ALKERMES ANNOUNCES TOPLINE RESULTS FROM LONG-TERM,
OPEN-LABEL
SAFETY AND DURABILITY OF TREATMENT EFFECT STUDY OF LYBALVI®
(OLANZAPINE AND SAMIDORPHAN)
    * ALKERMES PLC: RESULTS DEMONSTRATED THAT LYBALVI WAS
GENERALLY
WELL TOLERATED
    * ALKERMES PLC: SAFETY PROFILE OF LYBALVI WAS CONSISTENT
WITH
PREVIOUS STUDIES
    * ALKERMES PLC: OVERALL, 60% OF PATIENTS REPORTED AN ADVERSE
EVENT
(AE); MOST AES WERE MILD TO MODERATE IN SEVERITY

Source text for Eikon:  ID:nPn2bd3jRa 
Further company coverage:  ALKS.O 

 ((Reuters.Briefs@thomsonreuters.com;))